Tri Chemical Laboratories (4369) Q2 2027 earnings summary

Executive summary

• Net sales for the six months ended July 31, 2026, rose 18.8% year-over-year to ¥14,705 million, with operating profit up 20.8% to ¥3,838 million and profit attributable to owners of parent up 21.5% to ¥3,373 million.

• Comprehensive income increased 14.0% year-over-year to ¥3,237 million.

Financial highlights

• Gross profit for the period was ¥5,329 million, up from ¥4,717 million year-over-year.

• Ordinary profit increased 19.1% to ¥4,526 million compared to the same period last year.

• Basic earnings per share rose to ¥103.81 from ¥85.45 year-over-year.

• Cash and deposits increased to ¥10,078 million from ¥7,279 million as of January 31, 2026.

• Net cash provided by operating activities was ¥4,877 million, up from ¥2,728 million year-over-year.

Outlook and guidance

• Full-year net sales forecast is ¥29,500 million, up 23.5% year-over-year, with operating profit projected at ¥7,450 million (up 26.2%) and profit attributable to owners of parent at ¥6,570 million (up 19.1%).

• Basic earnings per share for the full year is forecast at ¥202.17.

• Annual dividend per share is forecast at ¥35.00.